Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689246 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 3 study, sponsored by TauRx Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 891
- Enrollment target
NCT01689246: Completed Phase 3 study, sponsored by TauRx Therapeutics.
NCT01689246 is a Phase 3 study that has completed, run by TauRx Therapeutics. The registered enrollment target is 891 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01689246, a Phase 3 study, has completed, sponsored by TauRx Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 891 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
Interventions
- DRUG Placebo
- DRUG TRx0237 150 mg/day
- DRUG TRx0237 250 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 891 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01689246
The ClinicalTrials.gov registry entry for NCT01689246 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 891 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TauRx Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01689246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01689246 about?
NCT01689246 is a clinical study titled "Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease". The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
What is the current status of trial NCT01689246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 891 participants. The study started on 2013-01. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01689246?
The interventions under investigation include: Placebo (DRUG), TRx0237 150 mg/day (DRUG), TRx0237 250 mg/day (DRUG).
Who is sponsoring clinical trial NCT01689246?
This trial is sponsored by TauRx Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.